Iteos Therapeutics Net Income
| ITOSDelisted Stock | USD 10.15 0.00 0.00% |
Iteos Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Iteos Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Iteos Therapeutics' valuation are provided below:Iteos Therapeutics does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Iteos |
Search Suggestions
| IT | Gartner | Company |
| ITLXX | Voya Investors Trust | Money Market Fund |
| ITB | iShares Home Construction | ETF |
| ITC | ITC | Cryptocurrency |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Iteos Therapeutics reported net income of (134.41 Million). This is 139.38% lower than that of the Biotechnology sector and 291.89% lower than that of the Health Care industry. The net income for all United States stocks is 123.54% higher than that of the company.
Iteos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iteos Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics of similar companies.Iteos Therapeutics is currently under evaluation in net income category among its peers.
Iteos Fundamentals
| Return On Equity | -0.35 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | (61.62 M) | |||
| Shares Outstanding | 44.21 M | |||
| Shares Owned By Insiders | 0.34 % | |||
| Shares Owned By Institutions | 90.28 % | |||
| Number Of Shares Shorted | 2.06 M | |||
| Price To Earning | 50.50 X | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 12.78 X | |||
| Revenue | 35 M | |||
| EBITDA | (121.82 M) | |||
| Net Income | (134.41 M) | |||
| Cash And Equivalents | 791.86 M | |||
| Cash Per Share | 22.26 X | |||
| Total Debt | 5.1 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.42 X | |||
| Book Value Per Share | 12.90 X | |||
| Cash Flow From Operations | (98.18 M) | |||
| Short Ratio | 1.34 X | |||
| Earnings Per Share | (4.73) X | |||
| Target Price | 10.35 | |||
| Number Of Employees | 173 | |||
| Beta | 1.49 | |||
| Market Capitalization | 448.68 M | |||
| Total Asset | 686.98 M | |||
| Retained Earnings | (9.78 M) | |||
| Working Capital | 469.18 M | |||
| Net Asset | 686.98 M |
About Iteos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iteos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Iteos Stock
If you are still planning to invest in Iteos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Iteos Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |